Compugen Ltd. CGEN
2.09 USD 0.00 (+0.00%)
At closeNov 11, 2026, 4:00 PM EST
2.09 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
2.07 Day range 2.12
1.43 52-week range 3.24
- YTD
- +36.60%
- 1 year
- +21.51%
News
seekingalpha.com Compugen: COM701 Data On Track And Continued Bispecific Rilvegostomig Development Compugen Ltd. maintains a "Buy" rating, driven by advancing clinical programs and strong partnership with AstraZeneca for rilvegostomig. The company's lead asset, COM701, is on track for phase 1/2…
prnewswire.com Compugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe Summit HOLON, Israel, Nov. 10, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI,…
seekingalpha.com Compugen Ltd. (CGEN) Q3 2026 Earnings Call Transcript Compugen Ltd. (CGEN) Q3 2026 Earnings Call Transcript
marketbeat.com What Compugen (CGEN) Said on Its Q3 Earnings Call Compugen NASDAQ: CGEN has completed enrollment in a randomized trial of its ovarian cancer treatment candidate COM701 and expects to report results by the end of the first quarter of 2027, executives…
zacks.com Compugen (CGEN) Reports Q3 Loss, Beats Revenue Estimates Compugen (CGEN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.
benzinga.com Compugen Q3 EPS $(0.06) Beats $(0.08) Estimate, Sales $3.821M Beat $1.700M Estimate Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.08) by 25 percent. This is a 14.29 percent increase over losses of $(0.07) per…
prnewswire.com Compugen Reports Third Quarter 2026 Results MAIA-ovarian fully enrolled; results expected by end of Q1 2027 Phase 3 rilvegostomig high-level results from partner AstraZeneca anticipated in H2 2027 from ARTEMIDE-Biliary01 trial UnigenX™…
prnewswire.com Compugen to Participate in November Investor Conferences HOLON, Israel, Nov. 3, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI,…
benzinga.com HC Wainwright & Co. Reiterates Buy on Compugen, Maintains $4 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Compugen (NASDAQ:CGEN) with a Buy and maintains $4 price target.
defenseworld.net Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets Compugen (NASDAQ: CGEN) outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into…
prnewswire.com Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference HOLON, ISRAEL, Oct. 6, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI,…
marketbeat.com Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets Compugen NASDAQ: CGEN outlined the clinical rationale for its COM701 antibody in platinum-sensitive ovarian cancer and described an expansion of its AI-powered discovery platform into…
seekingalpha.com Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript Compugen Ltd. (CGEN) Discusses COM701 in Ovarian Cancer, MAIA Trial Preview, and UNIGEN Platform Advancements Transcript
defenseworld.net Compugen (NASDAQ:CGEN) versus MiMedx Group (NASDAQ:MDXG) Head-To-Head Comparison Compugen (NASDAQ: CGEN - Get Free Report) and MiMedx Group (NASDAQ: MDXG - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two…
prnewswire.com Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026 HOLON, Israel, Sept. 22, 2026 /PRNewswire/ -- Compugen Ltd.
prnewswire.com Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference HOLON, Israel, Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd.
zacks.com All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com Are Medical Stocks Lagging Compugen (CGEN) This Year? Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.
seekingalpha.com Compugen: Better Runway Ahead Of MAIA Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MAIA's interim analysis. In my view, MAIA remains the main value driver, which is why CGEN's runway…
seekingalpha.com Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
marketbeat.com Compugen Q2 Earnings Call Highlights Compugen NASDAQ: CGEN said its second-quarter 2026 progress included continued enrollment in its MAIA-ovarian study of COM701, advancing partner-led programs with AstraZeneca and Gilead, and a cash…
zacks.com Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates Compugen (CGEN) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.08 per share a year ago.
benzinga.com Compugen Q2 EPS $(0.07), Inline, Sales $2.602M Beat $1.606M Estimate Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 12.5 percent increase over losses of $(0.08) per share from the same period…
benzinga.com Compugen Presents Trial-In-Progress Poster On MAIA-Ovarian Adaptive Platform Trial Of COM701, Potential Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026 Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress…
benzinga.com Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026 Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will…
benzinga.com Compugen Q1 2026 Earnings Call: Complete Transcript 
benzinga.com Earnings Scheduled For May 18, 2026 - benzinga.com Compugen Q1 EPS $(0.08) Misses $(0.07) Estimate, Sales $2.176M Beat $2.095M Estimate Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is unchanged from the same period last year. The…
benzinga.com Lake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6 Lake Street analyst Chad Messer initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating and announces Price Target of $6.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Earnings Breakdown: Compugen Q4 - benzinga.com Compugen Q4 EPS $0.60 Beats $0.05 Estimate, Sales $67.332M Beat $1.357M Estimate Compugen (NASDAQ:CGEN) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.05 by 1100 percent. This is a 957.14 percent increase over losses of $(0.07) per…
- benzinga.com Earnings Scheduled For March 2, 2026
benzinga.com Uncovering Potential: Compugen's Earnings Preview 
benzinga.com This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - benzinga.com HC Wainwright & Co. Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $4 HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating and announces Price Target of $4.
- benzinga.com Compugen Agrees With AstraZeneca To Monetize Portion Of Compugen's Rilvegostomig Future Royalties Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen's innovative immuno-oncology pipeline and to reach potential key catalysts from internal and partnered…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com Compugen Q3 EPS $(0.07) Beats $(0.09) Estimate, Sales $1.891M Beat $1.469M Estimate Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.09) by 19.54 percent. This is a 800 percent decrease over earnings of $0.01 per…
benzinga.com Earnings Scheduled For November 10, 2025 
benzinga.com Compugen Publishes Pooled Data Showing COM701 Activity in Platinum-Resistant Ovarian Cancer Ahead of ESMO Presentation Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that pooled…- benzinga.com Compugen Q2 EPS $(0.08) Misses $(0.07) Estimate, Sales $1.257M Miss $3.952M Estimate Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 23.08 percent. This is a 300 percent decrease over losses of $(0.02)…
- benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Compugen Q1 EPS $(0.08) Misses $(0.06) Estimate, Sales $2.28M Miss $3.70M Estimate Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is unchanged from the same period last year. The…
- benzinga.com Earnings Scheduled For May 19, 2025
- benzinga.com Uncovering Potential: Compugen's Earnings Preview
- benzinga.com Compugen Q4 2024 GAAP EPS $(0.07) May Not Be Comparable To $0.07 Estimate, Sales $1.47M May Not Be Comparable To $17.43M Estimate Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.07 by 200 percent. This is a 163.64 percent decrease over earnings of $0.11 per…
- benzinga.com Earnings Scheduled For March 4, 2025
- benzinga.com Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use Of COM902 (Reduced FC Anti-TIGIT) With Anti-PD-1 And Anti-PVRIG Antibodies The company announced that the United States Patent and Trademark Office (USPTO) has granted the Company a new patent covering method of use for COM902, the Company's potential best-in-class reduced…
- benzinga.com Compugen Q3 2024 GAAP EPS $0.01 Misses $0.06 Estimate, Sales $17.132M Miss $17.862M Estimate Compugen (NASDAQ:CGEN) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.06 by 83.33 percent. The company reported quarterly sales of $17.132 million…